ClinicalTrials.gg
Active, not recruitingNCT07193953ALSFUS003Updated Nov 19, 2026

Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)

A Phase 1 interventional study of Next Generation Dome Helmet Focused Ultrasound and Intravenous immunoglobulin (IVIG), 10% solution for infusion in Amyotrophic Lateral Sclerosis and ALS, sponsored by Sunnybrook Health Sciences Centre. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Sunnybrook Health Sciences Centre · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada — 15 open to participants now, 25 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Canada.

Planned enrollment
68th of 72
6 · median 75
Started
2025
with 4 others
Phase 1
16 of 82
5 open now
Primary completion
2026-11
later than 7 of 24 live
Registered
74th of 82
by date
Lead sponsor
3 of 82
Sunnybrook Health Sciences Centre

Among the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, this one is the 68th largest by planned enrollment of the 72 interventional ones that give a count, is one of 5 that started in 2025, is one of 16 in phase 1, reaches primary completion later than 7 of the 24 other live ones, and was the 74th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

15 of the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the safety and feasibility of IVIg administration in conjunction with primary motor cortex BBB opening using the Next Generation Dome Helmet (NGDH) FUS in adult participants with ALS.

Read the detailed description

This study is a prospective, single-arm, open-label, multiple-ascending dose (MAD), phase I trial to evaluate safety, feasibility, pharmacodynamics, and pharmacokinetics of enhanced delivery of IVIg 0.4 or 0.8g/kg to the primary motor cortex in 6 patients with ALS by using a single BBB opening procedure targeting the primary motor cortex in both brain hemispheres. Six participants will be enrolled in two sequential cohorts. The first cohort (n = 3) will receive 0.4g/kg of IVIg divided in two doses, while the second cohort (n = 3) will receive a 0.8g/kg of IVIg divided in two doses. In both cohorts, the second dose of IVIg will be accompanied by a single BBB opening procedure targeting the primary motor cortex in both brain hemispheres with focused ultrasound (FUS) using Next Generation Dome Helmet and intravenous microbubbles (DEFINITY®, Lantheus Medical Imaging Canada, Inc., Montreal, QC, Canada). This FUS procedure will occur during 2 weeks after the first dose administration. Follow-up visits will occur over the span of 24 weeks from the first dose.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
  • ALS

Keywords

  • ALS
  • Focused Ultrasound
  • Blood Brain Barrier Opening
  • Intravenous Immunoglobulin
  • Motor Neuron Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with ALS as per the Gold Coast Criteria;
  2. Aged 18 years or older;
  3. Capable of providing and complying with study procedures;
  4. If taking Riluzole, on a stable dose for at least 4 weeks prior to Baseline;
  5. If taking Edaravone, on a stable dose of one completed cycle prior to Baseline;
  6. Respiratory Function Criterion:

    • Able to lie supine without BiPAP or breathing discomfort; OR
    • Forced vital capacity or slow vital capacity ≥50% of the predicted value for sex, height and age, if available
  7. Able to communicate sensations during the Dome FUS procedure.
  8. Qualified fit for the anesthesia by an anesthesiologist, .

Exclusion criteria

Exclusion Criteria:

  1. MRI findings:

    1. Active infection/inflammation
    2. Acute or chronic hemorrhages, specifically > 4 lobar microbleeds, and no siderosis or macrohemorrhages
    3. Tumor/space occupying lesion causing significant mass effect
    4. Meningeal enhancement
    5. Intracranial hypotension
  2. More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp
  3. Clips or other metallic implanted objects in the skull or the brain, except shunts
  4. Significant cardiac disease or unstable hemodynamic status including:

    1. Documented myocardial infarction within six months of screening
    2. Unstable angina on medication
    3. Unstable or worsening congestive heart failure
    4. below the lower limit of normal
    5. History of a hemodynamically unstable cardiac arrhythmia
    6. Cardiac pacemaker
    7. Severe hypertension (diastolic BP > 100 on medication)
    8. Patient has right-to-left, bidirectional, or transient right-to-left cardiac shunts
    9. observed on screening (QTc > 450 for men and > 470 for women)
  5. Uncontrolled hypertension (systolic > 150 and diastolic BP > 100 on medication)
  6. Patients should not take medications known to increase risk of hemorrhage (e.g., aspirin or class I and III anticoagulants) for at least 7 days prior to treatment or lumbar puncture; patients should not take Avastin for 30 days prior to treatment
  7. History of a bleeding disorder, coagulopathy or a history of spontaneous hemorrhage or use of anticoagulants, specifically recent thrombosis or stroke in past 3 months; abnormal coagulation profile ( \< 100,00/μl), PT (> 14 sec) or (> 36 sec), and INR > 1.3
  8. No more than 1 non-strategic lacune \<1.5 cm
  9. Known cerebral or systemic vasculopathy
  10. Significant depression and at potential risk of suicide
  11. Known sensitivity/allergy to gadolinium (an alternative product may be used) and DEFINITY®.
  12. Any to MRI scanning, including:

    1. Large participants not fitting comfortably into the scanner
    2. Difficulty lying supine and still for up to 3 hours in the MRI unit or claustrophobia
  13. Any contraindication to lumbar puncture for collection of cerebral spinal fluid, including:

    a. Intracranial hypotension

  14. Untreated, uncontrolled sleep apnea
  15. Impaired renal function with estimated \< 30 mL/min/1.73m2 or on dialysis.
  16. IVIg use in the previous 6 months.
  17. Live viral vaccination within the 30 days before study entry
  18. Currently, or in the last 3 months participated in a clinical trial delivering an product or non-approved use of a drug or device or in any other type of medical research.
  19. Respiratory: chronic pulmonary disorders e.g. severe emphysema, pulmonary vasculitis, or other causes of reduced pulmonary vascular cross-sectional area, patients with a history of drug allergies, uncontrolled asthma or hay fever, and multiple allergies where the benefit/risk of administering DEFINITY® is considered unfavorable by the study physicians in relation to the product monograph for DEFINITY®.
  20. Motor cortex atrophy deemed severe enough to limit targeting
  21. Previous major allergic or anaphylactic reaction to IVIg
  22. Known IgA deficiency with anti-IgA.
  23. Known frontotemporal dementia;
  24. Definitely or possibly pregnant (if applicable);
  25. Known auto-immune condition with or without neurological manifestations (e.g., multiple sclerosis (MS), systemic lupus erythematous (SLE), Rheumatoid arthritis).
  26. Current, planned or previous use of oral, intramuscular or intravenous drugs (such as prednisone, prednisolone, dexamethasone, triamcinolone, methylprednisolone, oxandrolone, and others), drugs (azathioprine, mycophenolate, tacrolimus, sirolimus, cyclophosphamide, and others) or NSAIDs (ibuprofen, naproxen, celecoxib, and others) in the past 30 days;
  27. Other unspecified reasons that, in the opinion of the Investigator or the Sponsor, make the participant unsuitable for enrollment
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Intravenous Immunoglobulin Administration using Focused Ultrasound

    ALS patients will be assigned to receive Intravenous Immunoglobulin (IVIg) and DEFINITY® microbubbles. The first three enrolled patients will participate in the first cohort, receiving 0.4g/kg divided in two doses. After a preliminary safety assessment of the first cohort, the next three successfully screened patients will be enrolled in the second cohort, receiving 0.8g/kg divided in two doses. The second IVIg dose in each cohort will be administered in combination with Next Generation Dome Helmet (NGDH) focused ultrasound (FUS) to transiently open the blood-brain barrier and enhance IVIg delivery to the primary motor cortex.

    Device: Next Generation Dome Helmet Focused Ultrasound · Drug: Intravenous immunoglobulin (IVIG), 10% solution for infusion · Drug: Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension

Interventions

  • DeviceNext Generation Dome Helmet Focused Ultrasound

    Two doses of IVIg will be administered 2 weeks apart. The first dose at Week 0 will be a standalone administration. The second dose at Week 2 will be combined with Next Generation Dome Helmet (NGDH) Focused Ultrasound (FUS) blood brain barrier (BBB) opening.

  • DrugImmunoglobulins, IntravenousStudies of Immunoglobulins, IntravenousImmunoglobulins, Intravenous pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Two doses of IVIg will be administered 2 weeks apart. The first dose at Week 0 will be a standalone administration. The second dose at Week 2 will be combined with Next Generation Dome Helmet (NGDH) Focused Ultrasound (FUS) blood brain barrier (BBB) opening. Cohort I will receive 0.2g/kg of IVIg at each dose. Cohort II will receive 0.4g/kg of IVIg at each dose. Privigen® IVIg comes in vials containing 10% active ingredient. It is supplied in 2.5 g (25 mL bottle), 5 g (50 mL bottle), 10 g (100 mL bottle), 20 g (200 mL bottle) or 40 g (400 mL bottle). The IVIg dose will be determined based on the patient's ideal body weight.

  • DrugDefinity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension

    DEFINITY® Perflutren Injectable Microbubbles is an ultrasound contrast imaging agent that will be used for blood brain barrier opening during focused ultrasound. These microbubbles will be injected during the focused ultrasound procedure on the day of the second IVIg dose.

06

What researchers measure

Primary outcomes

  1. Safety of IVIg in patients with ALS

    This will be assessed up through the incidence of drug-related adverse events, serious adverse events, and discontinuations due to adverse events after Intravenous Immunoglobulin (IVIg) administration.

    Time frame: During and after IVIg administration at Week 0 and Week 2 Day 1 until Week 24.

  2. Safety of DEFINITY® microbubbles

    This will be assessed up through the incidence of drug-related adverse events, serious adverse events, and discontinuations due to adverse events after DEFINITY® infusion during focused ultrasound (FUS) blood brain barrier (BBB) opening.

    Time frame: During and after DEFINITY® administration at Week 2 Day 1 until Week 24.

  3. Feasibility of FUS BBB opening in the motor cortex

    This will be measured as detectable gadolinium enhancement at the arm, leg and bulbar regions of the motor cortex bilaterally following FUS with posterior normalization.

    Time frame: During and after Week 2 Day 1 FUS BBB opening until Week 24.

  4. Safety of FUS BBB opening in the motor cortex

    Incidence of BBB opening-related and FUS-related adverse events, serious adverse events, incidence of asymptomatic or symptomatic radiologic complication, such as evidence of bleeding or swelling after FUS, incidence of electrographic complication, such as epileptiform discharges on EEG, or accelerated ALS disease progression, defined as ≥ 6-point decline in the ALSFRS-R scores from Baseline to week 8.

    Time frame: From up to 30 days before Week 0 to Week 24.

Secondary outcomes

  1. Neurofilament light chain (NfL) levels in blood plasma and cerebrospinal fluid

    Change in concentration of serum neurofilaments from Baseline to Week 24

    Time frame: From up to 30 days before Week 0 to Week 24.

  2. Inflammatory markers in blood and cerebrospinal fluid

    Change in cerebrospinal fluid (CSF) and blood inflammatory markers, including but not limited to TNF-α, IL-1β, IL-2, IL-6, IL-8, IL-17, CHIT1, CHI3L1, CHI3L2, TGF-β, IL-10, and CRP

    Time frame: From up to 30 days before Week 0 to Week 24.

Other outcomes

  1. Pharmacokinetics Outcome - Immunoglobulin G Concentration

    Change in the cerebrospinal fluid (CSF)/whole blood ratio of Immunoglobulin G (IgG) concentration. This will serve as a pharmacokinetics outcome of enhanced IVIg delivery to the central nervous system after blood brain barrier opening.

    Time frame: From up to 30 days before Week 0 to Week 24.

  2. Exploratory Outcomes - ALSFRS-R scores

    A ≥ 4-point increase in the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) scores or significant clinical improvement at week 8.

    Time frame: From up to 30 days before Week 0 to Week 24.

  3. Exploratory Outcomes - Changes in levels of cerebral chemicals measured using Magnetic Resonance Spectroscopy

    Changes in cerebral chemicals through Magnetic Resonance Spectroscopy (MRS). These include N-acetylaspartate (NAA), total choline (Cho), total creatine (Cr), myo-inositol (Ino), Glutamate (Glu), and Gamma-aminobutyric acid (GABA). All measurements use the same units.

    Time frame: From up to 30 days before Week 0 to Week 24.

  4. Pharmacokinetics Outcome - Neurofilament light chain levels

    Change in cerebrospinal fluid and blood neurofilament light chain (NfL) post Next Generation Dome Helmet Focused Ultrasound (FUS) procedure, from week 2 to 24. This will serve as a pharmacokinetic outcome of NfL behavior post FUS procedure.

    Time frame: From up to 30 days before Week 0 to Week 24.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Nov 2026, 19 months after the start.

Of 30 non-industry phase 1 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 41. This study's planned 19 months is below that.

Counting every sponsor, half of 70 studies reached it within 21 months; a quarter within 13 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2025
First posted
Sep 26, 2025
StartActual
Apr 15, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
May 30, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07193953
Collaborators
Focused Ultrasound Foundation
Responsible party
Dr. Nir Lipsman (Chief of Hurvitz Brain Sciences Program, Director of Harquail Centre for Neuromodulation, Director of Neurosurgery Residency Program, Principal Investigator, Associate Professor, Sunnybrook Health Sciences Centre) — Principal investigator
First posted
Sep 26, 2025
Start date
Apr 15, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion